Enhancing magnetorheological effect using bimodal suspensions in the singlemultidomain limit

We demonstrate a new route to enhance the magnetorheological effect using bimodal suspensions in the single-multidomain limit. Experimental results are satisfactorily compared to 3D finite element method simulations. The physical reason behind this enhancement is the coating of the larger particles by the smaller ones due to the remnant magnetization of the latter.This work was supported by MAT 2016-78778-R and PCIN 2015-051 projects (FEDER FUNDS and MINECO, Spain). A J F Bombard is grateful to FAPEMIG grants: APQ-01824-17, PEE-00081-16, RED-00144-16, ETC-00043-15, PEP-00231- 15, APQ-00463-11 and RDP-00164-10. J R Morillas acknowledges FPU14/01576 fellowship

Enhancing magnetorheological effect using bimodal suspensions in the singlemultidomain limit

We demonstrate a new route to enhance the magnetorheological effect using bimodal suspensions in the single-multidomain limit. Experimental results are satisfactorily compared to 3D finite element method simulations. The physical reason behind this enhancement is the coating of the larger particles by the smaller ones due to the remnant magnetization of the latter.This work was supported by MAT 2016-78778-R and PCIN 2015-051 projects (FEDER FUNDS and MINECO, Spain). A J F Bombard is grateful to FAPEMIG grants: APQ-01824-17, PEE-00081-16, RED-00144-16, ETC-00043-15, PEP-00231- 15, APQ-00463-11 and RDP-00164-10. J R Morillas acknowledges FPU14/01576 fellowship

Magnetorheology of Carbonyl Iron Dispersions in 1‑Alkyl-3-methylimidazolium Ionic Liquids

In this work, a range of ionic liquids (IL), all based on 1-alkyl-3-methylimidazolium, [EMIM]⁺, and [BMIM]⁺ cations, with different anions, [NTf₂]⁻, [CF₃SO₃]⁻, [SCN]⁻, [BF₄]⁻, [PF₆]⁻, and [CH₃COO]⁻, were used as carrier fluids to prepare magnetorheological (MR) fluids with 30 vol % carbonyl iron powder (CIP), grade EW (BASF SE), without additives. IL-MR fluids were characterized in the presence of magnetic fields with conventional steady shear stress ramps, constant shear rate magnetosweeps, and strain amplitude oscillatory shear tests. In the absence of magnetic fields, samples were subjected to temperature sweep (from +80 to −20 °C), settling, and redispersibility tests. We conclude that, under large enough magnetic field strengths, above 10 kA/m, there is not a significant effect of the IL employed, in terms of MR effect or MR performance, both in steady shear as well as oscillatory shear. On the other hand, for long shelf life, without applied magnetic field at rest, [EMIM]⁺[CF₃SO₃]⁻, [BMIM]⁺[SCN]⁻, and [BMIM]⁺[CH₃COO]⁻ are not good candidates as carrier fluids for MR fluids, since they are very difficult to redisperse because of existing specific chemical interactions with the particle surface. In terms of settling stability, [BMIM⁺]­[PF₆]⁻ and [BMIM]⁺[CH₃COO]⁻ presented slower settling rates, because of their higher viscosities; however, the sedimentation curves collapse when normalized by the viscosity of the IL. Overall, the presence of fluorinated anions, such as [NTf₂]⁻, [BF₄]⁻, and [PF₆]⁻ facilitates redispersibility, as demonstrated by penetration tests

The DM-scope registry: a rare disease innovative framework bridging the gap between research and medical care

International audienceBackground: The relevance of registries as a key component for developing clinical research for rare diseases (RD) and improving patient care has been acknowledged by most stakeholders. As recent studies pointed to several limitations of RD registries our challenge was (1) to improve standardization and data comparability; (2) to facilitate interoperability between existing RD registries; (3) to limit the amount of incomplete data; (4) to improve data quality. This report describes the innovative concept of the DM-Scope Registry that was developed to achieve these objectives for Myotonic Dystrophy (DM), a prototypical example of highly heterogeneous RD. By the setting up of an integrated platform attractive for practitioners use, we aimed to promote DM epidemiology, clinical research and patients care management simultaneously.Results: The DM-Scope Registry is a result of the collaboration within the French excellence network established by the National plan for RDs. Inclusion criteria is all genetically confirmed DM individuals, independently of disease age of onset. The dataset includes social-demographic data, clinical features, genotype, and biomaterial data, and is adjustable for clinical trial data collection. To date, the registry has a nationwide coverage, composed of 55 neuromuscular centres, encompassing the whole disease clinical and genetic spectrum. This widely used platform gathers almost 3000 DM patients (DM1 n = 2828, DM2 n = 142), both children (n = 322) and adults (n = 2648), which accounts for > 20% of overall registered DM patients internationally. The registry supported 10 research studies of various type i.e. observational, basic science studies and patient recruitment for clinical trials.Conclusion: The DM-Scope registry represents the largest collection of standardized data for the DM population. Our concept improved collaboration among health care professionals by providing annual follow-up of quality longitudinal data collection. The combination of clinical features and biomolecular materials provides a comprehensive view of the disease in a given population. DM-Scope registry proves to be a powerful device for promoting both research and medical care that is suitable to other countries. In the context of emerging therapies, such integrated platform contributes to the standardisation of international DM research and for the design of multicentre clinical trials. Finally, this valuable model is applicable to other RDs

The DM-scope registry: a rare disease innovative framework bridging the gap between research and medical care

International audienceBackground: The relevance of registries as a key component for developing clinical research for rare diseases (RD) and improving patient care has been acknowledged by most stakeholders. As recent studies pointed to several limitations of RD registries our challenge was (1) to improve standardization and data comparability; (2) to facilitate interoperability between existing RD registries; (3) to limit the amount of incomplete data; (4) to improve data quality. This report describes the innovative concept of the DM-Scope Registry that was developed to achieve these objectives for Myotonic Dystrophy (DM), a prototypical example of highly heterogeneous RD. By the setting up of an integrated platform attractive for practitioners use, we aimed to promote DM epidemiology, clinical research and patients care management simultaneously.Results: The DM-Scope Registry is a result of the collaboration within the French excellence network established by the National plan for RDs. Inclusion criteria is all genetically confirmed DM individuals, independently of disease age of onset. The dataset includes social-demographic data, clinical features, genotype, and biomaterial data, and is adjustable for clinical trial data collection. To date, the registry has a nationwide coverage, composed of 55 neuromuscular centres, encompassing the whole disease clinical and genetic spectrum. This widely used platform gathers almost 3000 DM patients (DM1 n = 2828, DM2 n = 142), both children (n = 322) and adults (n = 2648), which accounts for > 20% of overall registered DM patients internationally. The registry supported 10 research studies of various type i.e. observational, basic science studies and patient recruitment for clinical trials.Conclusion: The DM-Scope registry represents the largest collection of standardized data for the DM population. Our concept improved collaboration among health care professionals by providing annual follow-up of quality longitudinal data collection. The combination of clinical features and biomolecular materials provides a comprehensive view of the disease in a given population. DM-Scope registry proves to be a powerful device for promoting both research and medical care that is suitable to other countries. In the context of emerging therapies, such integrated platform contributes to the standardisation of international DM research and for the design of multicentre clinical trials. Finally, this valuable model is applicable to other RDs